Romero, Miguel E. jimenezGallego, Maria CamachoSerrato, Jose c. navarroSanchez Hurtado, Miguel A.Santotoribio, Jose D.2025-01-072025-01-072021-08-010250-7005https://hdl.handle.net/10668/25155Background/Aim: The aim of the study was to evaluate the combined treatment with abiraterone acetate and prednisone (AA+P) in patients with castration resistant prostate cancer (mCPRC), and to identify the survival prognostic factors. Patients and Methods: Patients diagnosed with mCPRC not previously treated with chemotherapy and administered with AA+P were classified into two groups: those with lower and higher survival rates (at 30 months vs. 60 months). Results: A total of 53 patients were studied at the time of mCRPC diagnosis. Patients with the highest survival rate had suffered prostate cancer for >45 months. At the time of initial prostate cancer diagnosis, they belonged to the risk groups 1-4, had pain intensity measured according to the brief pain inventory (BPI) scale of 0-2, were treated with AA+P>16 months, and had the following tumour marker serum levels: LDH baseline 45 months. At the time of initial prostate cancer diagnosis, they belonged to the risk groups 1-4, had pain intensity measured according to the brief pain inventory (BPI) scale of 0-2, were treated with AA+P>16 months, and had the following tumour marker serum levels: LDH baseline 16 months, and had the following tumour marker serum levels: LDH baselineenProstate cancercastration-resistantabiraterone acetateprednisonechemo-naivesurvivalprognostic modelsClinical-outcomesPlus prednisoneAntigenMenModelEnzalutamideCou-aa-302Diagnosisresearch article34281859open access10.21873/anticanres.151921791-7530https://ar.iiarjournals.org/content/anticanres/41/8/3955.full.pdf720243100004